|
1Z2M
Crystal Structure of ISG15, the Interferon-Induced Ubiquitin Cross Reactive Protein
Deposited 2005-03-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
0–154(155 aa)
|
Mutation:c78s
|
OS4 OSMIUM 4+ ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;292 K;Tris-HCl buffer, PEG4K, MgCl2, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 2.50 Å
R-free 0.223
|
|
2HJ8
Solution NMR structure of the C-terminal domain of the interferon alpha-inducible ISG15 protein from Homo sapiens. Northeast Structural Genomics target HR2873B
Deposited 2006-06-30
|
Different construct
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
78–156(79 aa)
Fragment:ISG15 C-terminal domain (8.9 kDa), Ubiquitin-like 2
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.5;293 K;Ionic strength (raw mmCIF value) 50 mM ammonium citrate, 5 mM CaCl2;Pressure ambient
NMR sample composition
0.81 mM U-13C,15N HR2873B, 50 mM ammonium citrate, 5 mM CaCl2, 1x protease inhibitor, 0.02% NaN3, pH 6.5, 5% D2O / 95% H2O | 5% D2O / 95% H2O
NMR sample composition
0.9 mM 5%-13C,U-15N HR2873B, 50 mM ammonium citrate, 5 mM CaCl2, 1x protease inhibitor, 0.02% NaN3, pH 6.5, 5% D2O / 95% H2O | 5% D2O / 95% H2O
|
Resolution not provided
|
|
3PHX
OTU Domain of Crimean Congo Hemorrhagic Fever Virus in complex with ISG15
Deposited 2010-11-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
79–156(78 aa)
Fragment:UNP residues 79-156
|
Not recorded
|
ZN ZINC ION × 12
ACY ACETIC ACID × 2
NEH ETHANAMINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;10% PEG8K, 0.2M zinc acetate, 0.1M MES sodium salt, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.60 Å
R-free 0.192
|
|
3PHX
OTU Domain of Crimean Congo Hemorrhagic Fever Virus in complex with ISG15
Deposited 2010-11-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
79–156(78 aa)
Fragment:UNP residues 79-156
|
Not recorded
|
ZN ZINC ION × 12
ACY ACETIC ACID × 2
NEH ETHANAMINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;10% PEG8K, 0.2M zinc acetate, 0.1M MES sodium salt, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.60 Å
R-free 0.192
|
|
3PSE
Structure of a viral OTU domain protease bound to interferon-stimulated gene 15 (ISG15)
Deposited 2010-12-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
1–156(156 aa)
|
Mutation:C78S
|
4LJ 1.7.6 3-bromanylpropan-1-amine × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;293 K;100 mM MES, 23% PEG6000, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å
R-free 0.224
|
|
3R66
Crystal structure of human ISG15 in complex with NS1 N-terminal region from influenza virus B, Northeast Structural Genomics Consortium Target IDs HX6481, HR2873, and OR2
Deposited 2011-03-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–157(157 aa)
Chain D
1–157(157 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;15% PEG3350,
1% dioxane, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å
R-free 0.265
|
|
3RT3
Complex of influenza virus protein with host anti-viral factor
Deposited 2011-05-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain B
1–158(158 aa)
|
Mutation:C78S
|
SIN SUCCINIC ACID × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;20% PEG 8000, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.01 Å
R-free 0.243
|
|
3SDL
Crystal structure of human ISG15 in complex with NS1 N-terminal region from influenza B virus, Northeast Structural Genomics Consortium Target IDs HX6481, HR2873, and OR2
Deposited 2011-06-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–157(157 aa)
Chain D
1–157(157 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 7.5;293 K;15% PEG3350, 1% dioxane, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K, EVAPORATION
|
Resolution 2.29 Å
R-free 0.261
|
|
5TL6
Crystal structure of SARS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
Deposited 2016-10-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
80–157(78 aa)
Fragment:C-terminal domain (UNP residues 80-157)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
ZN ZINC ION × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;0.1 M lithium sulfate, 0.1 M Bis-tris [pH 6.5], 22% PEG 3350, supplemented with 30% (v/v) glycerol additive in a 1:5 dilution
|
Resolution 2.62 Å
R-free 0.250
|
|
5TL6
Crystal structure of SARS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
Deposited 2016-10-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
80–157(78 aa)
Fragment:C-terminal domain (UNP residues 80-157)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;0.1 M lithium sulfate, 0.1 M Bis-tris [pH 6.5], 22% PEG 3350, supplemented with 30% (v/v) glycerol additive in a 1:5 dilution
|
Resolution 2.62 Å
R-free 0.250
|
|
5W8T
Crystal structure of MERS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
Deposited 2017-06-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
80–156(77 aa)
|
Not recorded
|
AYE prop-2-en-1-amine × 1
ZN ZINC ION × 5
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;200 mM CaCl2, 100 mM NaO2C2H3 pH 4.6, 28% (v/v) MPD
|
Resolution 2.76 Å
R-free 0.224
|
|
5W8T
Crystal structure of MERS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
Deposited 2017-06-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
80–156(77 aa)
|
Not recorded
|
AYE prop-2-en-1-amine × 1
ZN ZINC ION × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;200 mM CaCl2, 100 mM NaO2C2H3 pH 4.6, 28% (v/v) MPD
|
Resolution 2.76 Å
R-free 0.224
|
|
5W8U
Crystal structure of MERS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
Deposited 2017-06-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
80–156(77 aa)
Fragment:UNP residues 80-156
|
Not recorded
|
ZN ZINC ION × 3
AYE prop-2-en-1-amine × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;200 mM CaCl2, 100 mM NaO2C2H3 pH 4.6, 28% (v/v) MPD
|
Resolution 2.41 Å
R-free 0.237
|
|
5W8U
Crystal structure of MERS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
Deposited 2017-06-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
80–156(77 aa)
Fragment:UNP residues 80-156
|
Not recorded
|
ZN ZINC ION × 3
AYE prop-2-en-1-amine × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;200 mM CaCl2, 100 mM NaO2C2H3 pH 4.6, 28% (v/v) MPD
|
Resolution 2.41 Å
R-free 0.237
|
|
6BI8
X-ray structure of MERS coronavirus papain-like protease in complex with human ISG15
Deposited 2017-11-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
1–156(156 aa)
|
Mutation:C78S
|
PGE TRIETHYLENE GLYCOL × 2
ZN ZINC ION × 1
GOL GLYCEROL × 2
AYE prop-2-en-1-amine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.3;293.15 K;0.25 M Potassium Citrate, pH 8.3
20% PEG3350
|
Resolution 2.29 Å
R-free 0.215
|
|
6BI8
X-ray structure of MERS coronavirus papain-like protease in complex with human ISG15
Deposited 2017-11-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
1–156(156 aa)
|
Mutation:C78S
|
PGE TRIETHYLENE GLYCOL × 2
ZN ZINC ION × 1
GOL GLYCEROL × 3
AYE prop-2-en-1-amine × 1
CIT CITRIC ACID × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.3;293.15 K;0.25 M Potassium Citrate, pH 8.3
20% PEG3350
|
Resolution 2.29 Å
R-free 0.215
|
|
6FFA
FMDV Leader protease bound to substrate ISG15
Deposited 2018-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
79–155(77 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
GOL GLYCEROL × 5
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;2 M Ammonium Sulfate
0.2 M Sodium potassium tartrate tetrahydrate
0.1 M Sodium citrate tribasic (pH 5.6)
|
Resolution 1.50 Å
R-free 0.186
|
|
6XA9
SARS CoV-2 PLpro in complex with ISG15 C-terminal domain propargylamide
Deposited 2020-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
79–157(79 aa)
Fragment:C-terminal domain (UNP residues 79-157)
|
Mutation:G176 replaced with propargylamide
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
GOL GLYCEROL × 3
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;0.2 M lithium sulfate, 25% PEG3350, 0.1 M Bis-Tris chloride, pH 6.5
|
Resolution 2.90 Å
R-free 0.231
|
|
6XA9
SARS CoV-2 PLpro in complex with ISG15 C-terminal domain propargylamide
Deposited 2020-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
79–157(79 aa)
Fragment:C-terminal domain (UNP residues 79-157)
|
Mutation:G176 replaced with propargylamide
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
GOL GLYCEROL × 3
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;0.2 M lithium sulfate, 25% PEG3350, 0.1 M Bis-Tris chloride, pH 6.5
|
Resolution 2.90 Å
R-free 0.231
|
|
6XA9
SARS CoV-2 PLpro in complex with ISG15 C-terminal domain propargylamide
Deposited 2020-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain F
79–157(79 aa)
Fragment:C-terminal domain (UNP residues 79-157)
|
Mutation:G176 replaced with propargylamide
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
GOL GLYCEROL × 2
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;0.2 M lithium sulfate, 25% PEG3350, 0.1 M Bis-Tris chloride, pH 6.5
|
Resolution 2.90 Å
R-free 0.231
|
|
7RBS
The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with human ISG15
Deposited 2021-07-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
2–157(156 aa)
|
Not recorded
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.02 M MgCl2, 0.1 M HEPES buffer, 22% poly(acrylicacid sodium salt) 5100
|
Resolution 2.98 Å
R-free 0.236
|
|
7RBS
The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with human ISG15
Deposited 2021-07-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
2–157(156 aa)
|
Not recorded
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.02 M MgCl2, 0.1 M HEPES buffer, 22% poly(acrylicacid sodium salt) 5100
|
Resolution 2.98 Å
R-free 0.236
|
|
7RBS
The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with human ISG15
Deposited 2021-07-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain F
2–157(156 aa)
|
Not recorded
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.02 M MgCl2, 0.1 M HEPES buffer, 22% poly(acrylicacid sodium salt) 5100
|
Resolution 2.98 Å
R-free 0.236
|
|
7RBS
The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with human ISG15
Deposited 2021-07-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain H
2–157(156 aa)
|
Not recorded
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.02 M MgCl2, 0.1 M HEPES buffer, 22% poly(acrylicacid sodium salt) 5100
|
Resolution 2.98 Å
R-free 0.236
|
|
7RBS
The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with human ISG15
Deposited 2021-07-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain J
2–157(156 aa)
|
Not recorded
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.02 M MgCl2, 0.1 M HEPES buffer, 22% poly(acrylicacid sodium salt) 5100
|
Resolution 2.98 Å
R-free 0.236
|
|
7S6P
The crystal structure of human ISG15
Deposited 2021-09-14
|
Different construct
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
2–157(156 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.04 M potassium phosphate, 16% PEG8000, 20% glycerol
|
Resolution 2.15 Å
R-free 0.268
|
|
7S6P
The crystal structure of human ISG15
Deposited 2021-09-14
|
Different construct
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
2–157(156 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.04 M potassium phosphate, 16% PEG8000, 20% glycerol
|
Resolution 2.15 Å
R-free 0.268
|
|
7S6P
The crystal structure of human ISG15
Deposited 2021-09-14
|
Different construct
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
2–157(156 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.04 M potassium phosphate, 16% PEG8000, 20% glycerol
|
Resolution 2.15 Å
R-free 0.268
|
|
7S6P
The crystal structure of human ISG15
Deposited 2021-09-14
|
Different construct
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain D
2–157(156 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.04 M potassium phosphate, 16% PEG8000, 20% glycerol
|
Resolution 2.15 Å
R-free 0.268
|
|
7S6P
The crystal structure of human ISG15
Deposited 2021-09-14
|
Different construct
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain E
2–157(156 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.04 M potassium phosphate, 16% PEG8000, 20% glycerol
|
Resolution 2.15 Å
R-free 0.268
|
|
7S6P
The crystal structure of human ISG15
Deposited 2021-09-14
|
Different construct
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain F
2–157(156 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.04 M potassium phosphate, 16% PEG8000, 20% glycerol
|
Resolution 2.15 Å
R-free 0.268
|
|
8OIF
Structure of the UBE1L activating enzyme bound to ISG15 and UBE2L6
Deposited 2023-03-22
|
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain I
1–157(157 aa)
|
Not recorded
|
AMP ADENOSINE MONOPHOSPHATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å
|
|
8SE9
Cryo-EM structure of a double loaded human UBA7-UBE2L6-ISG15 thioester mimetic complex (Form 2)
Deposited 2023-04-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain B
1–157(157 aa)
Chain D
1–157(157 aa)
|
Mutation:C78S
Mutation:C78S
|
AMP ADENOSINE MONOPHOSPHATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
8SEA
Cryo-EM structure of a double loaded human UBA7-UBE2L6-ISG15 thioester mimetic complex (Form 1)
Deposited 2023-04-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain B
1–157(157 aa)
Chain D
1–157(157 aa)
|
Mutation:C78S
Mutation:C78S
|
AMP ADENOSINE MONOPHOSPHATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
8SEB
Cryo-EM structure of a single loaded human UBA7-UBE2L6-ISG15 adenylate complex
Deposited 2023-04-08
|
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
1–157(157 aa)
|
Mutation:C78S
|
AMP ADENOSINE MONOPHOSPHATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.24 Å
|
|
8SV8
Cryo-EM structure of a double loaded human UBA7-UBE2L6-ISG15 thioester mimetic complex from a composite map
Deposited 2023-05-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain B
1–157(157 aa)
Chain D
1–157(157 aa)
|
Mutation:C78S
Mutation:C78S
|
AMP ADENOSINE MONOPHOSPHATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.38 Å
|
|
9NN9
ISG15 complexed with nanobody
Deposited 2025-03-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–157(157 aa)
Fragment:residues 1-157
|
Mutation:C78S
|
EDO 1,2-ETHANEDIOL × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;292 K;25 % PEG 3350, 0.1 M trisodium citrate pH 5.6, 0.2 M ammonium sulfate
|
Resolution 2.59 Å
R-free 0.244
|
|
9NN9
ISG15 complexed with nanobody
Deposited 2025-03-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
1–157(157 aa)
Fragment:residues 1-157
|
Mutation:C78S
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;292 K;25 % PEG 3350, 0.1 M trisodium citrate pH 5.6, 0.2 M ammonium sulfate
|
Resolution 2.59 Å
R-free 0.244
|
|
9NN9
ISG15 complexed with nanobody
Deposited 2025-03-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain E
1–157(157 aa)
Fragment:residues 1-157
|
Mutation:C78S
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;292 K;25 % PEG 3350, 0.1 M trisodium citrate pH 5.6, 0.2 M ammonium sulfate
|
Resolution 2.59 Å
R-free 0.244
|